

November 15, 2023

Zhengbin (Bing) Yao, Ph.D.
Chief Executive Officer
ArriVent Biopharma, Inc.
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073

Inc.

Draft Registration Statement on Form S-1
31, 2023

Re: ArriVent Biopharma,
Amendment No. 2 to
Submitted October
CIK 0001868279

Dear Zhengbin (Bing) Yao:

We have reviewed your amended draft registration statement and have the following comments.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to this letter and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 2 to Draft Registration Statement on Form S-1
Prospectus Summary
Overview, page 1

1. We note your disclosure that you received Breakthrough Therapy Designation from the FDA in October 2023. Please include balancing disclosure in the Prospectus Summary that this Designation does not increase the likelihood that furmonertinib will ultimately receive FDA approval for any indication.
Furmonertinib, page 2

2. We note your response to comment 3 and re-issue in part. Please balance your disclosure on pages 3 and 4 that furmonertinib "has been observed to be generally well tolerated" in multiple clinical trials with a description of all serious adverse events and quantify the number of each type of event.

Zhengbin (Bing) Yao, Ph.D.
ArriVent Biopharma, Inc.
November 15, 2023
Page 2

3. Please include clarifying disclosure in the Prospectus Summary that your statements about the FURLONG trial relate to a clinical trial in China conducted by Allist, which resulted in the approval of furmonertinib in China as a first-line therapy in patients with locally advanced or metastatic NSCLC with classical EGFRm.
Our Pipeline, page 2

4. Please revise the block of text under your pipeline table to more clearly explain which programs each note applies to. As currently drafted, it is not clear how

the text applies to
the above pipeline table and to which programs it applies. For example,
it is not clear if
the first row of the pipeline table corresponds to the sentence in the
below text block
concerning the FAVOUR and FURVENT trials. We would not object to the use
of a key.
Our Strategy, page 3

5. We note your revised disclosure in response to comment 5, specifically
that your
investigation of NSCLC EGFR exon 20 insertion mutations as a first-line
therapy is based
on the ongoing FAVOUR Phase 1b study and the ongoing FURVENT Phase 3
study. We
also note your revised disclosure that no Phase 2 study has been
conducted for this
indication. Please expand your discussion of the Phase 3 FURVENT clinical
trial in the
Prospectus Summary to include disclosure that clinical development
announcements by
Allist in the ongoing FAVOUR Phase 1b study may adversely affect your
clinical
development plan. We note risk factor disclosure to this effect on page
31. Ensure that this
discussion also discloses when the final results of this Phase 1b trial
are expected and
whether you intend to complete a Phase 2 trial for this indication.
Director Independence, page 162

6. Please reconcile your disclosure concerning director independence with
your revised
disclosure on page 164 that Dr. Carl Gordon does not meet the
requirements of
independence applicable to audit committee members of a listed issuer
under Rule 10A-3
under the Exchange Act.
Please contact Li Xiao at 202-551-4391 or Kevin Vaughn at 202-551-3494
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Dillon Hagius at 202-551-7967 or Suzanne Hayes at 202-551-3675 with any other
questions.

FirstName LastNameZhengbin (Bing) Yao, Ph.D.
Corporation Finance
Comapany NameArriVent Biopharma, Inc.
Sciences
November 15, 2023 Page 2
cc: John Rudy
FirstName LastName

Sincerely,
Division of
Office of Life